Compare GGR & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GGR | ADAG |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | Taiwan | China |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.6M | 84.8M |
| IPO Year | N/A | 2021 |
| Metric | GGR | ADAG |
|---|---|---|
| Price | $3.16 | $1.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 21.9K | ★ 47.9K |
| Earning Date | 02-12-2026 | 08-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $280,211,000.00 | $103,204.00 |
| Revenue This Year | N/A | $6,983.06 |
| Revenue Next Year | $6.15 | $36.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.72 | $1.30 |
| 52 Week High | $10.15 | $3.16 |
| Indicator | GGR | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 54.55 |
| Support Level | N/A | $1.50 |
| Resistance Level | N/A | $1.83 |
| Average True Range (ATR) | 0.00 | 0.13 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 86.90 |
Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.